FOLD - Amicus Therapeutics sees 2023 revenue growth of 21% Y/Y; issues 2024 strategic outlook
2024-01-08 02:13:20 ET
- Amicus Therapeutics: The Right Play Now
- Amicus Therapeutics beats Q3 top and bottom line estimates; raises FY23 Galafold revenue outlook
- Seeking Alpha’s Quant Rating on Amicus Therapeutics
For further details see:
Amicus Therapeutics sees 2023 revenue growth of 21% Y/Y; issues 2024 strategic outlook